Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

17.56 +0.55 (+3.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,795,104
Open 17.10
Bid (Size) 17.20 (1)
Ask (Size) 17.56 (1)
Prev. Close 17.01
Today's Range 16.94 - 17.84
52wk Range 6.010 - 25.29
Shares Outstanding 60,717,176
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Globant, Doximity, Applied Materials And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
IBD 50 Stock Travere Therapeutics Nosedived On An FDA Decision — Here's Why
Analysts are still bullish on the company's chances of being the first to win approval for an FSGS drug. 
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety

Performance

YTD
-7.4%
-7.4%
1 Month
+16.2%
+16.2%
3 Month
-22.5%
-22.5%
6 Month
+1.0%
+1.0%
1 Year
+184.6%
+184.6%

More News

Read More
Top movers in Friday's pre-market session
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Earnings Scheduled For May 1, 2025
Via Benzinga
Travere Therapeutics's Earnings: A Preview
Via Benzinga
Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Travere Stock Nosedives As FDA Schedules Advisory Meeting For Kidney Drug's Supplemental Use: Retail Shrugs Off Worries
Via Stocktwits
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Thursday's after hours session: top gainers and losers
Via Chartmill
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS
From Travere Therapeutics, Inc.
Via Business Wire
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics to Participate at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via Business Wire
Is TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) following the Minervini trend for explosive growth?
Via Chartmill
Travere Therapeutics Reports First Quarter 2025 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics to Report First Quarter 2025 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
Assessing Travere Therapeutics: Insights From 8 Financial Analysts
Via Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval
Via Investor's Business Daily
Exposures Product Safety
The Analyst Verdict: Travere Therapeutics In The Eyes Of 7 Experts
Via Benzinga
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
From Travere Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Travere Therapeutics, Inc. - Common Stock publicly traded?
Yes, Travere Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Travere Therapeutics, Inc. - Common Stock trade on?
Travere Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Travere Therapeutics, Inc. - Common Stock?
The ticker symbol for Travere Therapeutics, Inc. - Common Stock is TVTX on the Nasdaq Stock Market
What is the current price of Travere Therapeutics, Inc. - Common Stock?
The current price of Travere Therapeutics, Inc. - Common Stock is 17.56
When was Travere Therapeutics, Inc. - Common Stock last traded?
The last trade of Travere Therapeutics, Inc. - Common Stock was at 05/20/25 04:00 PM ET
What is the market capitalization of Travere Therapeutics, Inc. - Common Stock?
The market capitalization of Travere Therapeutics, Inc. - Common Stock is 1.07B
How many shares of Travere Therapeutics, Inc. - Common Stock are outstanding?
Travere Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.